Camrelizumab – NSCLC | HongKong DengYue Medicine

Camrelizumab Application Scope

Camrelizumab is a humanized monoclonal antibody targeting the PD‑1 receptor, designed to enhance immune response against tumors.

Characteristics

• Ingredients: Camrelizumab

• Properties:

  • IgG4‑based anti‑PD‑1 checkpoint inhibitor

  •  Blocks PD‑1 interaction with PD‑L1/PD‑L2 to activate T‑cells

• Packaging Specification: Usually supplied as single‑use vials; exact size varies by country label

• Storage: Store refrigerated at 2–8°C; protect from light.

• Expiry Date: ​Consult vial label—typically 24 months from manufacture under proper storage

• Executive Standard:

  • Complies with national pharmacopeia

  • Regulatory standards of the manufacturing country

• Approval Number: Exact NMPA number via local label.

• Date of Revision: Depends on the latest prescribing document—please refer to the regulatory website or product insert

• Manufacturer: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Guidelines for the Use of Camrelizumab

• Dosage and Administration:

  • Refer to the official label

  • 200 mg IV is commonly given every 2–3 weeks (based on clinical studies).

  • Pre-infusion: check vial, dilute per label, administer via IV infusion over ~30–60 min.

• Adverse Reactions:

  • Immune‑related events: dermatitis, colitis, pneumonitis, hepatitis, endocrine toxicities.

  • Common: fatigue, infusion reactions, rash, diarrhea, hypothyroidism.

  • Refer to the full safety data in the official label.

• Contraindications:

  • No absolute contraindications listed

  • Caution with active autoimmune disease or transplant recipients.

• Precautions:

  • Monitor for immune‑mediated toxicities.

  • Suspend therapy for grade ≥3 adverse events.

  • Use caution in special populations (e.g., hepatic/renal impairment, pregnancy).

Camrelizumab Interactions

• Drug Interactions:

  • No known CYP enzyme interactions.

  • Concomitant immunosuppressants (e.g., high‑dose steroids) may reduce efficacy.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.